AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00502970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24 weeks Interferon
Description: 24 weeks Interferon Tiw with Ribavirin
Study NCT03139578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test 8.5BC
Description: senofilcon A contact lenses with 8.5 base curve
Study NCT03139578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test 9.0BC
Description: senofilcon A contact lenses with 9.0 base curve
Study NCT03139578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control 8.5BC
Description: narafilcon A contact lenses with 8.5 base curve
Study NCT03607929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: variability
Description: Other solutions
Study NCT01040325 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TD Vaccine System
Description: TD Vaccine System Containing Placebo Product
Study NCT03086720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite
Description: Application of 10% sodium hypochlorite (60 seconds) after the etching procedure and before the adhesive system.
Study NCT04681612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MSNA
Description: Assessed via Muscle Microneurography during the first 14 days of the acute phase.~Indices: busts/min, busts/100bpm
Study NCT04681612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate Variability
Description: Assessed via 24hr ECG monitoring during the first 14 days of the acute phase. Indices: Time-domain, Frequency-domain, Non-linear
Study NCT03086720 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
Study NCT02856074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prise de sang
Study NCT02856074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life questionnaire
Study NCT03726190 — intervention group
Intervention type: PROCEDURE
Intervention: Oblique Lateral Lumbar Fusion
Description: Oblique lateral lumbar interbody fusion (OLLIF) is a lumbar spinal fusion. OLLIF is performed with the patient in the prone position and employs an oblique lateral approach that enables the instrumentation to pass through Kambin's triangle which is defined as the space between the exiting nerve, the superior border of the caudal vertebra, and the superior articulating process of the inferior facet. This approach may be performed without direct visualization, guided by electrophysiological monitoring and biplanar fluoroscopy. During the approach, a blunt probe is used to make contact with the disc, followed by a series of gentle dilations. Discectomy is performed through a 10-mm access portal. The cage is inserted under continued electrophysiological monitoring and fluoroscopy.
Study NCT04681612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Pressure Variability
Description: Assessed via Ambulatory BPM during the first 14 days of the acute phase. Indices: SD, wSD, ARV, CV
Study NCT03281421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.
Study NCT03281421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.
Study NCT04681612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CMR
Description: Cardiac Magnetic Resonance during the first 14 days of the acute phase. Assessment of oedema, Late Gadolinium Enhancement ischaemic pattern. Assessment of cardiac function parameters
Study NCT04681612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: History, Lab, clinical and hemodynamic parameters
Description: 1. Description of event, 2. Risk factors, 3. Medical history, 4. ECG parameters, 5. ECHO parameters, 6. Hemodynamic parameters of acute phase and hospitalization, 7. Coronary angiogram paraemeters, 7. Complete lab parameter assessment, 8. Thrombofilia assessment, 9. SF-12 QoL and Anxiety and Depression Scale (HADS) questionnaires
Study NCT02633800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab
Description: Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed by a maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
Study NCT01001897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
Study NCT02633800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400 mg/mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
Study NCT02633800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
Study NCT02633800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 100 mg/m\^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
Study NCT02633800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin at 100 mg/m\^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
Study NCT01001897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
Study NCT00800098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: herbal topical cream
Study NCT02633800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
Study NCT02633800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
Study NCT02633800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match patritumab
Study NCT04585932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Given PO
Study NCT04585932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT04585932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: Given SC
Study NCT04585932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC
Study NCT01685307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test meal
Description: test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
Study NCT04585932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT04585932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT04585932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00800098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: herbal topical cream
Study NCT04585932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04585932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04585932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04585932 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT03565510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Protein Diet
Description: The high-protein diet is composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement.
Study NCT04371783 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immediate FET
Description: FET is performed in the first menstrual cycle following the stimulated IVF cycle
Study NCT04371783 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed FET
Description: FET is performed in the second menstrual cycle following the stimulated IVF cycle
Study NCT02538185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NanoJect device (DebioJect™)
Description: The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
Study NCT02538185 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NanoJect device (DebioJect™)
Description: The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
Study NCT02538185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)
Description: The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
Study NCT02538185 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)
Description: The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
Study NCT02495597 — intervention group
Intervention type: OTHER
Intervention: no intervention - just observational
Study NCT03139578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control 9.0BC
Description: narafilcon A contact lenses with 9.0 base curve
Study NCT04061564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagal nerve stimulation
Description: The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
Study NCT02538185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
Description: The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
Study NCT02538185 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
Description: The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
Study NCT02538185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaccin rabique Pasteur®
Study NCT02538185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaccin rabique Pasteur®
Study NCT02538185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride (NaCl) 0,9%; B. Braun
Study NCT02538185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride (NaCl) 0,9%; B. Braun
Study NCT02526654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heidelberg Edge Perimeter
Description: HEP measures peripheral vision
Study NCT02526654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Octopus Visual Field
Description: OVF measures peripheral vision
Study NCT04061564 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vagal nerve stimulation
Description: The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
Study NCT00557882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: synthetic polypropylene mesh
Description: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
Study NCT01931475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally
Study NCT01931475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT00968643 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Given in multiple fractions or as a single fraction
Study NCT01314755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IMPACT
Description: IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an 'immune-enhancing' feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
Study NCT01314755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: An iso-caloric, iso-nitrogenous control feed
Study NCT04203706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofunctional imaging
Description: Subjects will be submitted to a functional neuroimaging scanning procedure
Study NCT02933983 — intervention group
Intervention type: OTHER
Intervention: no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients
Study NCT00735683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATHX-105 phosphate
Description: includes diet, physical activity, and lifestyle modification
Study NCT02526654 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: OCT measures retinal nerve fiber layer thickness
Study NCT00968643 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given in multiple fractions or as a single fraction
Study NCT00735683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: includes diet, physical activity, and lifestyle modification
Study NCT04398589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: We used 9.5 ml of 0.75% ropivacaine and 0.5 ml (50 μg) of dexmedetomidine each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
Study NCT03983512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PULSTA TPV System
Description: PULSTA transcatheter pulmonary valve replacement.
Study NCT04412044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab Injection [Nucala]
Description: Patients receive monthly injection with 100 mg mepolizumab
Study NCT04398589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: We used 9.5 ml of 0.75% ropivacaine and 0.5 ml normal saline each for preemptive suprascapular nerve block and axillary nerve block just before arthroscopic repair of rotator cuff tear.
Study NCT00589758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: 2D and 3D echocardiography
Study NCT00589758 — intervention group
Intervention type: OTHER
Intervention: Biomarker evaluation
Description: Blood and urine collected
Study NCT01164995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 and carboplatin
Description: Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
Study NCT01164033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO5045337
Description: single oral dose
Study NCT01164033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: single oral dose
Study NCT02742948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: IV ceftriaxone (2g) will be given to all participants
Study NCT02246127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Everolimus
Description: 10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02246127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Everolimus
Description: 10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02246127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STZ-5FU
Description: 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02246127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STZ-5FU
Description: 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01628029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo CBT
Study NCT01628029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride
Description: Given PO
Study NCT01628029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Undergo light therapy
Study NCT01628029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO
Study NCT01628029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00955032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency Repetitive Transcranial Magnetic Stimulation
Description: In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
Study NCT00955032 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
Study NCT01628029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Intervention
Description: Undergo sham light therapy
Study NCT01628029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Melatonin
Description: Given PO
Study NCT03900468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa™ PC and Percept™ PC Neurostimulation Systems
Description: Implanted DBS system consisting of a Neurostimulator, Leads, Extensions, and potential accessories including Burr Hole Devices, Clinician Tablet, Clinician Programmer Therapy Application Software, Clinician Programmer Communicator, Patient Programmer
Study NCT04319211 — intervention group
Intervention type: OTHER
Intervention: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.
Description: The study will include those who isolate themselves at home for fear of contracting Coronavirus disease or suspected of having it. The last three sections of the International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants. Parameters such as housework, home care and family care, rest, sports and leisure physical activities, sitting time will be evaluated. Short Form 12 (Short Form12- SF12) quality of life scale will be used to evaluate health-related quality of life. Beck Depression Scale will be applied to investigate the stress levels of the individuals participating in our study.
Study NCT01292954 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries
Description: low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period